Activation of Melanoma Differentiation-Associated Gene 5 Causes Rapid Involution of the Thymus

David Anz, Raffael Thaler, Nicolas Stephan, Zoe Waibler, Michael J. Trauscheid, Christoph Scholz, Ulrich Kalinke, Winfried Barchet, Stefan Endres and Carole Bourquin
J Immunol May 15, 2009, 182 (10) 6044-6050; DOI: https://doi.org/10.4049/jimmunol.0803809

Abstract

In the course of infection, the detection of pathogen-associated molecular patterns by specialized pattern recognition receptors in the host leads to activation of the innate immune system. Whereas the subsequent induction of adaptive immune responses in secondary lymphoid organs is well described, little is known about the effects of pathogen-associated molecular pattern-induced activation on primary lymphoid organs. Here we show that activation of innate immunity through the virus-sensing melanoma differentiation-associated gene 5 (MDA-5) receptor causes a rapid involution of the thymus. We observed a strong decrease in thymic cellularity associated with characteristic alterations in thymic subpopulations and microanatomy. In contrast, immune stimulation with potent TLR agonists did not lead to thymic involution or induce changes in thymic subpopulations, demonstrating that thymic pathology is not a general consequence of innate immune activation. We determined that suppression of thymocyte proliferation and enhanced apoptosis are the essential cellular mechanisms involved in the decrease in thymic size upon MDA-5 activation. Further, thymic involution critically depended on type I IFN. Strikingly however, no direct action of type I IFN on thymocytes was required, given that the decrease in thymic size was still observed in mice with a selective deletion of the type I IFN receptor on T cells. All changes observed were self-limiting, given that cessation of MDA-5 activation led to a rapid recovery of thymic size. We show for the first time that the in vivo activation of the virus-sensing MDA-5 receptor leads to a rapid and reversible involution of the thymus.

The innate immune system represents the first line of defense against viral infections. Initiation of antiviral immune responses is critically dependent on the activation of innate pattern recognition receptors that recognize evolutionarily conserved structures, termed pathogen-associated molecular patterns (1). In particular, the cytoplasmic helicases melanoma differentiation-associated gene 5 (MDA-5)4 and retinoic acid inducible gene I (RIG-I) play an essential role in sensing viral RNA and in generating immune responses to RNA viruses (2, 3, 4). Whereas RIG-I recognizes viral ssRNA with a 5′-triphosphate motif and short dsRNA, MDA-5 is activated by long dsRNA (3, 4, 5). Virally encoded RNA can also be detected by another family of pattern recognition receptors, the TLRs; long dsRNA and ssRNA sequences can activate innate immunity through the endosomally located TLR3 and TLR7, respectively (6, 7, 8, 9, 10). Stimulation of pattern recognition receptors leads to the initiation of an innate immune response characterized by the production of a large panel of proinflammatory cytokines (7, 11). Among these, the type I IFNs IFN-α and IFN-β play an essential role in preventing viral spread through the induction of apoptosis and the suppression of cell proliferation (12, 13). In secondary lymphoid organs such as the spleen, the lymph nodes, or the GALT, stimulation by pathogen-associated molecular patterns leads to the generation of adaptive T and B cell responses against pathogens.

In contrast to the well-characterized effects of pattern recognition receptor activation in secondary lymphoid organs, the consequences of innate immune activation on the primary lymphoid organs, the bone marrow and thymus, are still unclear. Within these organs, continuous proliferation of pluripotent progenitors is necessary to supply the organism with immune cells and to maintain organ integrity. In the bone marrow, proliferation is suppressed during viral infections, an effect that is in part mediated by the antiproliferative action of type I IFN (14). Indeed, neutropenia, a hallmark of bone marrow suppression, is one of the most common side effects of IFN-α treatment in hepatitis C-infected patients (15, 16).

Little is known about the impact of innate immune activation on structure and function of the thymus in vivo. The development of T cells from bone marrow progenitors takes place exclusively in the thymus, and an efficient thymic output of lymphocytes is therefore crucial for the maintenance of the naive T cell pool in the periphery (17, 18, 19). An important fraction of self-reactive T cells is deleted in the thymus by apoptosis, and thymic cellularity is maintained by vigorous proliferation of immature thymocytes. Viral infections are in some cases associated with in vivo alterations of thymic function; thymic atrophy and a reduced T cell output are seen in HIV-infected patients (20) and have also been described in a mouse model of reovirus infection (21). The mechanisms involved remain, however, unclear. We describe here for the first time that in vivo activation of the virus-sensing MDA-5 receptor causes involution of the thymus.

Materials and Methods

Mice

Female C57BL/6 and BALB/c mice were purchased from Harlan-Winkelmann. Experiments were done on C57BL/6 mice unless indicated otherwise. Type I IFN receptor-deficient mice (IFNAR−/−) were backcrossed 20 times on the C57BL/6 background (22). CD4cre+/−IFNARflox/flox mice, CD19cre+/−IFNARflox/flox, and MDA-5−/− mice have been previously described (23, 24). Mice were at least 8 wk of age at the onset of experiments. Animal studies were approved by the local regulatory agency (Regierung von Oberbayern, Munich, Germany).

Ligands for MDA-5 and TLRs

Polyinosinic acid-polycytidylic acid (poly(I:C); InvivoGen) was applied i.p. (250 μg in 250 μl of distilled water). The fully phosphothioate-modified CpG oligonucleotide 1826 (5′-TCCATGACGTTCCTGACGTT-3′; Coley Pharmaceutical Group), LPS (Sigma-Aldrich), and R848 (Alexis Biochemicals) were injected s.c. into the flank in 200 μl of PBS (100, 5, and 20 μg, respectively).

Flow cytometry

Single-cell suspensions were stained with anti-CD3-Pacific Blue or PerCP, anti-CD4-PE-Cy7, anti-CD8-allophycocyanin-Alexa750, anti-CD25-PE and anti-CD44-allophycocyanin (all BD Biosciences). Events were measured on a FACSCanto II flow cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar).

Histology

Specimens were fixed in formalin before embedding in paraffin blocks. The resulting tissue sections were stained with H&E. For immunofluorescence analysis, 5-μm frozen cryosections were fixed in acetone before blocking with 10% goat serum. Rat anti-mouse CD4 (Biolegend) and rat anti-mouse CD8 (BD Biosciences) were used as primary Abs. Because both Abs are derived from the same species, we used a protocol based on sequential application of primary Abs and detection with Fab fragments. First, we applied the anti-CD8 Ab followed by detection with biotinylated goat-anti-rat IgG Fab fragments; these Fab fragments fully saturate the first primary Ab and thus prevent binding of subsequently applied anti-rat secondary Abs (25). After detection with a Cy2-conjugated streptavidin, the second primary Ab (anti-CD4) was applied followed by detection with rhodamine red X-conjugated mouse anti-rat IgG. To prevent cross-reactions of the goat anti-rat Fab fragments to endogenous mouse IgG, tissues were generally blocked with (Fab) goat anti-mouse IgG before staining. Images were obtained using a fluorescence microscope (Axiovert 2000; Carl Zeiss) and processed using Adobe Photoshop for adjustment of contrast and size.

Intrathymic FITC injection

Intrathymic injections of FITC were performed as described (26). Poly(I:C) was applied at days 1 and 3 after FITC injection, and organs were isolated at day 4 to assess thymocyte emigration to the periphery.

In vivo BrdU proliferation assay

Mice received three i.p. injections of 2 mg of BrdU in PBS (Sigma-Aldrich) at 6-h intervals. Thymus and spleen were isolated 6 h after the last injection of BrdU. After surface staining, single-cell suspensions were fixed and permeabilized using a ready-mixed kit from Ebioscience. BrdU incorporation was detected using FastImmune Anti-BrdU FITC with DNAse according to the manufacturer’s instructions (BD Biosciences), and FITC+ cells were quantified by flow cytometry.

Detection of apoptotic cells

An Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences) was used for detection of apoptotic cells. After surface staining, single-cell suspensions of thymus and spleen were washed twice with PBS before resuspension in the provided buffer and incubation with annexin V and propidium iodide. Cells were subsequently analyzed by flow cytometry.

Statistical analysis

All data are presented as mean ± SEM and were analyzed as appropriate by the unpaired Student t test or the ANOVA test. Statistical analysis was performed using SPSS software.

Results

Stimulation of innate immunity through MDA-5 causes involution of the thymus

To investigate whether in vivo activation of innate immunity affects the thymus, we treated mice with the dsRNA molecule poly(I:C). Poly(I:C) stimulates the immune system through two different pathways mediated by activation of either the endosomal TLR3 or the cytoplasmic helicases RIG-I and MDA-5 (4, 5, 6, 24). Adult mice were injected twice with poly(I:C) at 3-day intervals, and organs were examined 24 h after the second injection. We observed a substantial decrease in the volume of the thymus (Fig. 1⇓A) reflected by a >3-fold reduction in thymic weight (Fig. 1⇓B). In contrast, no decrease in weight was observed for the spleen (Fig. 1⇓B) and the peripheral lymph nodes (data not shown), demonstrating that this effect was selective for the thymus. The rapid involution was due to a strong reduction in cellularity, whereby the average number of thymocytes dropped from >130 × 106 cells to <3 × 106 cells (Fig. 1⇓C). To determine which pattern recognition receptor was involved in poly(I:C)-induced thymic involution, we examined thymic pathology in mice deficient for MDA-5. This cytoplasmic helicase plays a crucial role in the recognition of many common viruses by the innate immune system (10). In striking contrast to wild-type mice, poly(I:C) treatment of MDA-5−/− mice did not affect the macroscopic aspect of the thymus and only slightly decreased thymic weight (Fig. 1⇓D), indicating an essential role for this receptor in thymic pathology. To investigate whether decrease of thymic size is a general consequence of innate immune activation, we treated mice with ligands for different TLRs. Although application of the TLR7 ligand R848 led to a moderate decrease in thymic weight, neither stimulation with the TLR4-activating LPS nor stimulation with the TLR9 ligand CpG DNA resulted in a significant decrease of thymic size (Fig. 1⇓E). All three TLR ligands are potent stimulators of innate immunity that efficiently induce production of proinflammatory cytokines and lymphocyte activation in vivo (7). Thus, in vivo immune activation through the cytoplasmic helicase MDA-5, but not through TLRs in general, rapidly leads to involution of the thymus.

FIGURE 1.
FIGURE 1.

MDA-5-induced decrease in size, weight, and cellularity of the thymus. A, Mice were treated twice (days 0 and 3) with poly(I:C) (pI:C), and organs were examined 24 h after the second injection. Macroscopic aspect of the thymus of five untreated (top row) and four poly(I:C)-treated (bottom row) mice; B, weight of the thymus and spleen: each data point represents one individual mouse, and the means are depicted as a bar; C, mean number of thymocytes for n = 5 (control) and n = 4 (poly(I:C)) mice per group. Error bars indicate SEM. D, Macroscopic aspect and means of thymic weight from n = 5 WT and MDA-5-deficient mice ± SEM. The means of untreated mice were set to 100%. E, Thymus weight of BALB/c mice 8 h after the last of two injections (days 0 and 3) of poly(I:C), R848 (ligand for TLR7), LPS (ligand for TLR4) and CpG (ligand for TLR9) for n = 5 mice per group. Results are representative of at least three independent experiments. ø = untreated; pI:C = poly(I:C). ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; n.s., not significant; comparison with untreated unless indicated by brackets; WT, wild type.

MDA-5-induced thymic suppression is characterized by a decrease in CD4+CD8+ double-positive (DP) thymocytes

The stages of T cell maturation within the thymus are characterized by the differential expression of surface markers. Immature progenitor cells are double-negative (DN) for both CD4 and CD8 upon immigration and can be further differentiated into four stages of maturation: the progenitor cells first express CD44 (DN1 cells), then become consecutively CD44+CD25+ (DN2), CD44−CD25+ (DN3), and finally CD44−CD25− (DN4). DN cells subsequently acquire double positivity for CD4 and CD8 in the thymic cortex and finally lose the expression of either CD4 or CD8 to leave the thymus as mature, single-positive T lymphocytes (17, 27). After treatment with poly(I:C), we observed a significant drop in the cell count for all major thymic populations (Fig. 2⇓A). In contrast, the loss in cellularity was prevented to a large extent in MDA-5-deficient mice after treatment with poly(I:C) in all thymic subpopulations including the DN subsets (Fig. 2⇓B). Proportional analysis demonstrated a strong decrease within the fraction of DP cells, dropping from >80% to <40% of all thymocytes, whereas a relative increase was seen within the single-positive cells (Fig. 2⇓C). These changes were nearly entirely absent in MDA-5-deficient mice stimulated with poly(I:C), confirming the essential role of the MDA-5 activation pathway for the suppressive effect of poly(I:C) on the thymus (Fig. 2⇓C). Stimulation with poly(I:C) further led to a relative increase in the DN1 compartment that was accompanied by a drop in the DN3 fraction (Fig. 2⇓D). Thus, the overall decrease in thymic cellularity by stimulation of innate immunity is characterized by a strong reduction of the DP cell fraction with specific changes within the DN cell subset. To examine whether the potent immune activation induced by synthetic TLR ligands could also modify the distribution of thymocyte subpopulations, we analyzed thymocyte fractions in mice treated with LPS, R848, or CpG. In striking contrast to mice treated with poly(I:C), the fraction of DP cells was not decreased in any of the three groups treated with TLR ligands (Fig. 2⇓E). Thus, stimulation of MDA-5, but not TLR activation, leads to a reduction of the DP thymocyte fraction.

FIGURE 2.
FIGURE 2.

Decrease in thymocyte subpopulations upon MDA-5 activation. Mice were treated with poly(I:C) as described in Fig. 1. Thymocytes were counted and analyzed by flow cytometry. A, Absolute cell numbers for thymocyte subpopulations, means of 5 mice ± SEM. B, Poly(I:C) (pI:C)-induced change in cell numbers (ratio of untreated to poly(I:C) treated) in the indicated thymocyte subpopulations of wild-type (WT; n = 4) and MDA-5-deficient (n = 5) mice. C, Proportions of thymocyte subpopulations in wild-type (n = 4) and MDA-5-deficient (n = 5) mice; means ± SEM are indicated as bars. D, Means of the proportions within DN thymocyte subsets (DN1, CD44+CD25−; DN2, CD44+CD25+; DN3, CD44−CD25+ and DN4, CD44−CD25−); n = 5 mice for each group ± SEM. E, Fraction of DP thymocytes of BALB/c mice 8 h after the last of two injections (days 0 and 3) of poly(I:C), R848 (ligand for TLR7), LPS (ligand for TLR4), and CpG (ligand for TLR9) for n = 5 mice per group. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; comparison with untreated unless indicated by brackets.

MDA-5-induced immune activation leads to a reduction of the thymic cortex and altered histomorphology

Histologically, the thymus is divided into a highly cellular cortex with strong proliferative activity and a medulla defined by a coarse reticulum with lower lymphocyte density (27). To assess changes in thymic microanatomy upon in vivo stimulation of innate immunity, organs from poly(I:C)-treated mice were examined by histology. Although both thymic cortex and medulla were markedly decreased in volume, the reduction of the cortex was clearly more pronounced, resulting in a decreased ratio of cortical to medullary space (Fig. 3⇓A). Furthermore, the corticomedullary border was blurred, resulting in a disorganized aspect of thymic microanatomy. Fluorescent double staining for CD4 (red) and CD8 (green) demonstrated a decrease in the DP-cell fraction in the cortex detected by a reduced merged (yellow) color signal (Fig. 3⇓B). To assess the importance of MDA-5-mediated signaling in histomorphological changes, thymi from MDA-5-deficient mice treated with poly(I:C) were examined. In contrast to wild-type mice, no histological alterations were observed in MDA-5-deficient mice (Fig. 3⇓C), confirming the essential role of MDA-5 for poly(I:C)-induced thymic pathology.

FIGURE 3.
FIGURE 3.

MDA-5-mediated histomorphological changes of the thymus. A, H&E-stained sections of the thymus 48 h after the second of two injections of poly(I:C). B, Cryosections of the thymus were double-stained with anti-CD4 and anti-CD8 mAbs. Images show the cortical areas of the thymus: CD4 (red); CD8 (green); DP cells (yellow merged color signal). C, Thymic histology from untreated and poly(IC)-treated wild-type or MDA-5-deficient mice. C, cortex; M, medulla.

Involution is caused by suppression of proliferation and enhanced apoptosis of thymocytes

The rapid thymocyte loss upon MDA-5 activation could be due either to enhanced emigration of thymocytes or to increased apoptosis of developing T lymphocytes. In addition, poly(I:C)-triggered antiproliferative effects on thymocytes could contribute to thymic involution. To explore the mechanisms involved, we first measured T cell emigration out of the thymus after treatment with poly(I:C). FITC was injected directly into the thymus (26), and peripheral lymphoid organs were analyzed 4 days later for the presence of FITC-positive recent thymic emigrants. Two applications of poly(I:C) did not increase the fraction of emigrated lymphocytes detected in the peripheral lymphoid organs (Fig. 4⇓). Instead, lymphocyte emigration was slightly reduced, albeit not significantly, after treatment with poly(I:C).

FIGURE 4.
FIGURE 4.

Recent thymic emigrants in secondary lymphoid organs after treatment with poly(I:C). All mice received intrathymic injections of FITC followed by two poly(I:C) applications (at days 1 and 3 after injection of FITC). The spleen and the peripheral lymph nodes (LN) were isolated 24 h after the last application of poly(I:C). The number of FITC+-emigrated lymphocytes was measured by flow cytometry. Bars indicate means of 5 control and 6 poly(I:C)-treated mice ± SEM. The decrease of FITC+ CD4+ and CD8+ cells upon poly(I:C) treatment is not significant.

To investigate whether innate immune activation affects T cell proliferation in the thymus, we quantified proliferating cells by measuring the in vivo incorporation of BrdU. DP thymocytes that represent the most abundant population in the thymus showed the highest proliferative activity in untreated mice (Fig. 5⇓A). Upon immunostimulation with poly(I:C), we observed a marked suppression of proliferation for DP cells and for single-positive CD8 cells (Fig. 5⇓A). The DN and CD4 subpopulations showed low baseline proliferation that was not significantly affected by poly(I:C) (data not shown). The level of proliferation in DP and CD8 cells tended to recover as early as 48 h after the last application of poly(I:C). In the spleen, we observed conversely an increase in the number of proliferating CD8 T cells and B cells upon poly(I:C) treatment, indicating that suppression of cellular proliferation is specific for the thymus (Fig. 5⇓A).

FIGURE 5.
FIGURE 5.

Decreased in vivo proliferation and enhanced apoptosis of thymocytes upon treatment with poly(I:C). Mice were treated twice (days 0 and 3) with poly(IC). A, BrdU was applied 18 h before the organs were taken. The percentage of BrdU+ cells was determined 24 or 48 h after the second injection of poly(I:C). Indicated thymocyte and splenocyte subsets were analyzed by flow cytometry. Bars indicate means of 4 to 5 mice ± SEM. B, Organs were examined 24 h after the second injection of poly(I:C) for the percentage of early apoptotic (annexin V+, propidium iodide−; top) and late apoptotic (annexin V+, propidium iodide+; bottom) thymocytes gated on the indicated subpopulations. Bars indicate means of 5 mice ± SEM. ∗, p < 0.05; ∗∗, p < 0.01; comparison with untreated.

To evaluate the role of apoptosis in thymic involution, we assessed the percentage of apoptotic cells within the thymocyte subpopulations upon treatment with poly(I:C). Early and late apoptosis was significantly enhanced in DP and DN thymocytes, respectively (Fig. 5⇑B). No changes in apoptosis were observed for T cells in the spleen (data not shown). Taken together, our results show that thymic involution following MDA-5 stimulation results from a marked decrease in thymocyte proliferation associated with increased rates of apoptosis.

MDA-5-mediated thymic suppression depends on the type I IFN receptor

Antiproliferative and proapoptotic effects are characteristic features of type I IFN activity. Recent studies in fetal thymic organ cultures suggested that type I IFN inhibits thymocyte development in vitro (28). To examine a possible involvement of type I IFN in MDA-5-mediated thymic reduction, we treated mice deficient for IFNAR with poly(I:C). In contrast to the decrease in thymic weight seen in wild-type animals, we observed no significant decrease in IFNAR-deficient mice (Fig. 6⇓, top). Further, the characteristic loss of DP thymocytes was completely absent in these mice. Because the receptor for type I IFN is expressed by a broad spectrum of cells in the organism (29), we investigated whether thymic involution is mediated through direct action of type I IFN on developing T cells. We used CD4-cre+/−IFNARflox/flox-transgenic mice in which the IFNAR is selectively deleted on all T cells. Loss of thymic weight and cellularity in these mice were comparable with those of wild-type animals (Fig. 6⇓, middle). To examine whether B cells, representing an important fraction of immune cells in the mouse, may be involved in type I IFN-mediated thymic involution, CD19-cre+/−IFNARflox/flox mice that lack IFNAR expression on B cells, were injected with poly(I:C). Here again, as in wild-type mice, thymic weight and the fraction of DP cells were strongly reduced (Fig. 6⇓, bottom). These data demonstrate that thymic involution is not mediated by the direct action of type I IFN on T cells or B cells.

FIGURE 6.
FIGURE 6.

IFNAR-dependent involution of the thymus upon treatment with poly(I:C). Mice were treated twice (days 0 and 3) with poly(I:C), and organs were examined 48 h after the last injection. The thymic weight and the fraction of DP thymocytes of wild-type (WT; n = 5), IFNAR−/− (n = 5), CD4cre+/−IFNARflox/flox (n = 7) and CD19cre+/−IFNARflox/flox (n = 4) mice are shown as means ± SEM; means of untreated mice were set to 100%. ∗, p < 0.05; ∗∗, p < 0.01; comparison to untreated.

Suppression of thymic cellularity occurs rapidly and is self-limiting

Typically, the secretion of type I IFN is an early and short-lasting event (2–48 h) upon viral infection or stimulation by synthetic ligands (30). Because thymic suppression is dependent on type I IFN, we examined whether poly(I:C)-mediated involution is reversible upon cessation of treatment by determining thymus weight at different times after a single application of poly(I:C). A significant reduction was observed as early as 24 h after stimulation (Fig. 7⇓A). Suppression was less pronounced than after two injections of poly(I:C) (Fig. 7⇓, A and B). After 3 days, an increase in thymus weight was detectable, and weight returned to initial levels 1 wk after stimulation (Fig. 7⇓A). Recovery was delayed after two consecutive applications of poly(I:C) and did not reach initial levels 10 days after the second injection (Fig. 7⇓B). All histological alterations observed during thymic involution were reversible, and the ratio of cortical to medullary tissue was restored 10 days after the last injection (Fig. 7⇓C). These results demonstrate that MDA-5-induced suppression of the thymus is self-limiting and organ integrity is restored within 10 days after cessation of immune stimulation.

FIGURE 7.
FIGURE 7.

Recovery of thymus weight and structure after treatment with poly(I:C) (p(I:C)). A, Time course of thymus weight in BALB/c mice after a single injection of poly(I:C) on day 0; mean of n = 4 mice for each time point. B, Development of thymus weight after two injections of poly(I:C); means of n = 4 for each group. C, Histology of the thymus 10 days after the last of two injections of poly(I:C). C, cortex; M, medulla. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001.

Discussion

Our results demonstrate that stimulation of innate immunity by in vivo activation of MDA-5 leads to involution of the thymus. Furthermore, we show that immune activation by a panel of potent TLR agonists neither caused involution of the thymus nor induced changes within the relative fractions of thymic subpopulations. Indeed, the only significant TLR-mediated effect observed was a mild decrease in thymic weight induced by two applications of the potent TLR7 ligand R848. These novel findings expand on recent results describing blockade of thymic output by stimulation with the dsRNA molecule poly(I:C) (31). In addition, our data support the concept that MDA-5, rather than TLR3 or RIG-I, is involved during the in vivo recognition of synthetic long dsRNA. Previous studies examining the relative importance of these receptors and their downstream signaling pathways for immune stimulation by poly(I:C) have focused on the induction of proinflammatory cytokines (4, 5, 24). Here we describe thymic pathology as a novel functional readout that reaffirms the importance of MDA-5 as an in vivo mediator of poly(I:C) activity. Taken together, our results show that in vivo activation of innate immunity through the cytoplasmic helicase MDA-5, but not through TLRs in general, leads to involution of the thymus.

Stimulation of pattern recognition receptors such as MDA-5, RIG-I, TLR3, or TLR7 with synthetic ligands mirrors the immune activation induced by infections with RNA viruses (2, 4). Infection of mice with reovirus, an RNA virus that activates innate immunity via RIG-I and MDA-5 (32), has been associated with atrophy of the thymus (21). In humans, a massive involution of the thymus was observed in children who died from acute infection with measles virus, a ssRNA virus that induces type I IFN via the MDA-5 receptor (33, 34, 35). Infection with HIV also leads to thymic damage and results in a reduced overall emigration of thymocytes that is reversible upon antiviral treatment (20, 36). Furthermore, a decrease in thymic cellularity has also been described in a model of T cell-restricted overexpression of lymphotoxins, proteins known to be induced upon viral infection (37). Taken together, these observations and our results suggest that viral infections may represent a natural trigger for rapid and reversible involution of the thymus. Furthermore, our results suggest that thymic involution may occur selectively upon infection with viruses known to activate innate immunity via MDA-5.

In our study, the synthetic dsRNA poly(I:C) causes thymic involution. This molecule is known as potent inducer of type I IFN (7), and we delineate here a key role for this cytokine in thymic suppression. It has been shown that plasmacytoid dendritic cells, the professional type I IFN producers, are abundantly present in the thymus. Isolated thymic plasmacytoid dendritic cells produce large amounts of type I IFNs upon viral stimulation and suppress the development of CD34+CD1a− thymic progenitor cells in coculture assays (38, 39). Inhibition of thymic development by IFN-α has also been shown in newborn mice, where treatment with an active IFN-α2/α1 hybrid molecule was associated with decreased cellularity of bone marrow and thymus (40). Additionally, type I IFN induced by poly(I:C) is reported to suppress fetal thymic organ cultures in vitro (28) and to block output of thymocytes in vivo (31). Here we demonstrate that type I IFN does not act directly on T cells, given that mice in which the IFNAR deficiency is restricted to T cells (CD4-Cre+/−IFNARflox/flox) show a decrease in thymic cellularity similar to that of wild-type mice upon stimulation with poly(I:C). Similarly, we observed no direct effects of type I IFN on B cells. This suggests that the site of action of type I IFN is on nonlymphoid cells that, once stimulated, suppress T cell development in the thymus. Among non-immune cells residing in the thymus, thymic epithelial cells (TEC) represent a population that plays an essential role in thymocyte development and proliferation (41, 42). It has been reported that type I IFN, by directly acting on TECs, induces phenotypical and functional alterations of these cells in vitro that may impair thymocyte proliferation (43). It has further been shown that TECs themselves have the ability to produce type I IFN in response to transfection with poly(I:C) in vitro (43). It is thus possible that TECs can respond to in vivo stimulation by poly(I:C) and produce type I IFN that could essentially contribute to the MDA-5-induced thymic involution. Because MDA-5 is expressed ubiquitously in all lymphoid and various nonlymphoid tissues (44), systemic production of type I IFN upon poly(I:C) treatment may additionally affect TEC function and, consequently, thymocyte development. Finally, we cannot exclude that the effects seen in DN thymocyte subset may result from a direct action by type I IFN: in CD4-Cre+/−IFNARflox/flox mice, the IFNAR is irreversibly deleted upon first expression of the CD4 Ag during T cell maturation, so that T lymphocyte precursors in the DN stage remain susceptible to type I IFN-mediated effects.

Activation of RIG-I-like helicases and TLRs has evolved as a promising strategy to activate the immune system for therapeutic purposes. We and others have shown that the ligand for TLR9, CpG, can be successfully used as an adjuvant for vaccination and CpG oligonucleotides are in clinical trials for the therapy of infectious and malignant diseases (45, 46, 47, 48). Further, TLR7 agonists support Ag-specific T and B cell activation (49) and are effectively used against cutaneous malignant or premalignant lesions (50). Stimulation of the RIG-I receptor using triphosphate RNA or of MDA-5 with poly(I:C) mediates potent antitumoral effects in mice (51, 52). Finally, type I IFN itself is used for the treatment of cancer and chronic viral infections as hepatitis (16, 53). All of these molecules could affect thymic cellularity in humans, in particular potent inducers of type I IFN such as ligands for MDA-5 or RIG-I. Thus, the impact on thymic function should be considered during therapeutic immune activation, specifically in the case of chronic treatment regimens.

Acknowledgments

We thank Nadja Sandholzer, Stefanie Bauer, and the entire immunology group at the Paul-Ehrlich-Institut for expert technical assistance.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This study was supported by grants from the Ludwig-Maximilians-Universität München Excellent Research Professorship (to S.E.), from the Else-Kröner Fresenius Foundation (to S.E. and C.B.), and from German Research Foundation Grants DFG En 169/7-2 and Graduiertenkolleg 1202 (to S.E. and C.B.), Excellence Cluster CIPSM 114 (to S.E.), BA3544/1-1 (to W.B.), and SFB-TR 36 (to S.E.). This work is part of the doctoral thesis of R.T. and N.S. supported by Graduiertenkolleg 1202.

  • ↵2 D.A. and R.T. contributed equally to this study.

  • ↵3 Address correspondence and reprint requests to Dr. Stefan Endres, Division of Clinical Pharmacology, Ludwig-Maximilians Universität, Ziemssenstrasse 1, 80336 Munich. E-mail address: endres{at}lmu.de

  • ↵4 Abbreviations used in this paper: MDA-5, melanoma differentiation-associated gene 5; RIG-I, retinoic acid-inducible gene I; IFNAR, type I IFN receptor; poly(I:C), polyinosinic-polycytidylic acid; DN, double negative; DP, double positive; TEC, thymic epithelial cells.

  • Received November 13, 2008.
  • Accepted March 11, 2009.

References

  1. ↵
    Medzhitov, R., C. A. Janeway, Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298.
    OpenUrlCrossRefPubMed
  2. ↵
    Takeuchi, O., S. Akira. 2007. Recognition of viruses by innate immunity. Immunol. Rev. 220: 214-224.
    OpenUrlCrossRefPubMed
  3. ↵
    Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. Akira, K. K. Conzelmann, M. Schlee, S. Endres, G. Hartmann. 2006. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, et al 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
    OpenUrlCrossRefPubMed
  5. ↵
    Kato, H., O. Takeuchi, E. Mikamo-Satoh, R. Hirai, T. Kawai, K. Matsushita, A. Hiiragi, T. S. Dermody, T. Fujita, S. Akira. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205: 1601-1610.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Alexopoulou, L., A. C. Holt, R. Medzhitov, R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738.
    OpenUrlCrossRefPubMed
  7. ↵
    Trinchieri, G., A. Sher. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7: 179-190.
    OpenUrlCrossRefPubMed
  8. ↵
    Hornung, V., M. Guenthner-Biller, C. Bourquin, A. Ablasser, M. Schlee, S. Uematsu, A. Noronha, M. Manoharan, S. Akira, A. de Fougerolles, S. Endres, G. Hartmann. 2005. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11: 263-270.
    OpenUrlCrossRefPubMed
  9. ↵
    Barton, G. M.. 2007. Viral recognition by Toll-like receptors. Semin. Immunol. 19: 33-40.
    OpenUrlCrossRefPubMed
  10. ↵
    Kawai, T., S. Akira. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7: 131-137.
    OpenUrlCrossRefPubMed
  11. ↵
    Kanzler, H., F. J. Barrat, E. M. Hessel, R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13: 552-559.
    OpenUrlCrossRefPubMed
  12. ↵
    Clemens, M. J.. 2003. Interferons and apoptosis. J. Interferon Cytokine Res. 23: 277-292.
    OpenUrlCrossRefPubMed
  13. ↵
    Petricoin, E. F., 3rd, S. Ito, B. L. Williams, S. Audet, L. F. Stancato, A. Gamero, K. Clouse, P. Grimley, A. Weiss, J. Beeler, et al 1997. Antiproliferative action of interferon-α requires components of T-cell-receptor signalling. Nature 390: 629-632.
    OpenUrlCrossRefPubMed
  14. ↵
    Rosenfeld, S. J., N. S. Young. 1991. Viruses and bone marrow failure. Blood Rev. 5: 71-77.
    OpenUrlCrossRefPubMed
  15. ↵
    Fried, M. W., J. Peter, K. Hoots, P. J. Gaglio, D. Talbut, P. C. Davis, N. S. Key, G. C. White, L. Lindblad, F. R. Rickles, T. C. Abshire. 2002. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 36: 967-972.
    OpenUrlPubMed
  16. ↵
    Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
    OpenUrlCrossRefPubMed
  17. ↵
    Zuniga-Pflucker, J. C.. 2004. T-cell development made simple. Nat. Rev. Immunol. 4: 67-72.
    OpenUrlCrossRefPubMed
  18. ↵
    Bourgeois, C., Z. Hao, K. Rajewsky, A. J. Potocnik, B. Stockinger. 2008. Ablation of thymic export causes accelerated decay of naive CD4 T cells in the periphery because of activation by environmental antigen. Proc. Natl. Acad. Sci. USA 105: 8691-8696.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Sebzda, E., S. Mariathasan, T. Ohteki, R. Jones, M. F. Bachmann, P. S. Ohashi. 1999. Selection of the T cell repertoire. Annu. Rev. Immunol. 17: 829-874.
    OpenUrlCrossRefPubMed
  20. ↵
    Ye, P., D. E. Kirschner, A. P. Kourtis. 2004. The thymus during HIV disease: role in pathogenesis and in immune recovery. Curr HIV Res. 2: 177-183.
    OpenUrlCrossRefPubMed
  21. ↵
    Onodera, T., T. Taniguchi, T. Tsuda, K. Yoshihara, S. Shimizu, M. Sato, A. Awaya, T. Hayashi. 1991. Thymic atrophy in type 2 reovirus infected mice: immunosuppression and effects of thymic hormone: thymic atrophy caused by reo-2. Thymus 18: 95-109.
    OpenUrlPubMed
  22. ↵
    Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Kamphuis, E., T. Junt, Z. Waibler, R. Forster, U. Kalinke. 2006. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108: 3253-3261.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R. A. Flavell, M. S. Diamond, M. Colonna. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 103: 8459-8464.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Brown, J. K., A. D. Pemberton, S. H. Wright, H. R. Miller. 2004. Primary antibody-Fab fragment complexes: a flexible alternative to traditional direct and indirect immunolabeling techniques. J. Histochem. Cytochem. 52: 1219-1230.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Staton, T. L., B. Johnston, E. C. Butcher, D. J. Campbell. 2004. Murine CD8+ recent thymic emigrants are αE integrin-positive and CC chemokine ligand 25 responsive. J. Immunol. 172: 7282-7288.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Ceredig, R., T. Rolink. 2002. A positive look at double-negative thymocytes. Nat. Rev. Immunol. 2: 888-897.
    OpenUrlCrossRefPubMed
  28. ↵
    Baron, M. L., D. Gauchat, R. La Motte-Mohs, N. Kettaf, A. Abdallah, T. Michiels, J. C. Zuniga-Pflucker, R. P. Sekaly. 2008. TLR ligand-induced type I IFNs affect thymopoiesis. J. Immunol. 180: 7134-7146.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Auerbuch, V., D. G. Brockstedt, N. Meyer-Morse, M. O'Riordan, D. A. Portnoy. 2004. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200: 527-533.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Biron, C. A., L. P. Cousens, M. C. Ruzek, H. C. Su, T. P. Salazar-Mather. 1998. Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. Adv. Exp. Med. Biol. 452: 143-149.
    OpenUrlPubMed
  31. ↵
    Demoulins, T., A. Abdallah, N. Kettaf, M. L. Baron, C. Gerarduzzi, D. Gauchat, S. Gratton, R. P. Sekaly. 2008. Reversible blockade of thymic output: an inherent part of TLR ligand-mediated immune response. J. Immunol. 181: 6757-6769.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Loo, Y. M., J. Fornek, N. Crochet, G. Bajwa, O. Perwitasari, L. Martinez-Sobrido, S. Akira, M. A. Gill, A. Garcia-Sastre, M. G. Katze, M. Gale, Jr. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82: 335-345.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    White, R. G., J. F. Boyd. 1973. The effect of measles on the thymus and other lymphoid tissues. Clin. Exp. Immunol. 13: 343-357.
    OpenUrlPubMed
  34. ↵
    Chino, F., H. Kodama, T. Ohkawa, Y. Egashira. 1979. Alterations of the thymus and peripheral lymphoid tissues in fatal measles: a review of 14 autopsy cases. Acta Pathol. Jpn. 29: 493-507.
    OpenUrlPubMed
  35. ↵
    Berghall, H., J. Siren, D. Sarkar, I. Julkunen, P. B. Fisher, R. Vainionpaa, S. Matikainen. 2006. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. Microbes Infect. 8: 2138-2144.
    OpenUrlCrossRefPubMed
  36. ↵
    Dion, M. L., J. F. Poulin, R. Bordi, M. Sylvestre, R. Corsini, N. Kettaf, A. Dalloul, M. R. Boulassel, P. Debre, J. P. Routy. 2004. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity 21: 757-768.
    OpenUrlCrossRefPubMed
  37. ↵
    Heikenwalder, M., M. Prinz, N. Zeller, K. S. Lang, T. Junt, S. Rossi, A. Tumanov, H. Schmidt, J. Priller, L. Flatz, T. Rulicke, et al 2008. Overexpression of lymphotoxin in T cells induces fulminant thymic involution. Am. J. Pathol. 172: 1555-1570.
    OpenUrlCrossRefPubMed
  38. ↵
    Gurney, K. B., A. D. Colantonio, B. Blom, H. Spits, C. H. Uittenbogaart. 2004. Endogenous IFN-α production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J. Immunol. 173: 7269-7276.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Schmidlin, H., W. Dontje, F. Groot, S. J. Ligthart, A. D. Colantonio, M. E. Oud, E. J. Schilder-Tol, M. Spaargaren, H. Spits, C. H. Uittenbogaart, B. Blom. 2006. Stimulated plasmacytoid dendritic cells impair human T-cell development. Blood 108: 3792-3800.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Lin, Q., C. Dong, M. D. Cooper. 1998. Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 187: 79-87.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Zamisch, M., B. Moore-Scott, D. M. Su, P. J. Lucas, N. Manley, E. R. Richie. 2005. Ontogeny and regulation of IL-7-expressing thymic epithelial cells. J. Immunol. 174: 60-67.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Anderson, G., N. C. Moore, J. J. Owen, E. J. Jenkinson. 1996. Cellular interactions in thymocyte development. Annu. Rev. Immunol. 14: 73-99.
    OpenUrlCrossRefPubMed
  43. ↵
    Vidalain, P. O., D. Laine, Y. Zaffran, O. Azocar, C. Servet-Delprat, T. F. Wild, C. Rabourdin-Combe, H. Valentin. 2002. Interferons mediate terminal differentiation of human cortical thymic epithelial cells. J. Virol. 76: 6415-6424.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Kang, D. C., R. V. Gopalkrishnan, L. Lin, A. Randolph, K. Valerie, S. Pestka, P. B. Fisher. 2004. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 23: 1789-1800.
    OpenUrlCrossRefPubMed
  45. ↵
    Bourquin, C., D. Anz, K. Zwiorek, A. L. Lanz, S. Fuchs, S. Weigel, C. Wurzenberger, P. von der Borch, M. Golic, S. Moder, et al 2008. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 181: 2990-2998.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Bourquin, C., S. Schreiber, S. Beck, G. Hartmann, S. Endres. 2006. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int. J. Cancer 118: 2790-2795.
    OpenUrlCrossRefPubMed
  47. ↵
    Krieg, A. M.. 2007. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184-1194.
    OpenUrlCrossRefPubMed
  48. ↵
    Krieg, A. M.. 2008. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27: 161-167.
    OpenUrlCrossRefPubMed
  49. ↵
    Bourquin, C., L. Schmidt, V. Hornung, C. Wurzenberger, D. Anz, N. Sandholzer, S. Schreiber, A. Voelkl, G. Hartmann, S. Endres. 2007. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 109: 2953-2960.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    van Seters, M., M. van Beurden, F. J. ten Kate, I. Beckmann, P. C. Ewing, M. J. Eijkemans, M. J. Kagie, C. J. Meijer, N. K. Aaronson, A. Kleinjan, et al 2008. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med. 358: 1465-1473.
    OpenUrlCrossRefPubMed
  51. ↵
    Poeck, H., R. Besch, C. Maihoefer, M. Renn, D. Tormo, S. S. Morskaya, S. Kirschnek, E. Gaffal, J. Landsberg, J. Hellmuth, et al 2008. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14: 1256-1263.
    OpenUrlCrossRefPubMed
  52. ↵
    Tormo, D., A. Ferrer, P. Bosch, E. Gaffal, E. Basner-Tschakarjan, J. Wenzel, T. Tuting. 2006. Therapeutic efficacy of antigen-specific vaccination and Toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66: 5427-5435.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Tagliaferri, P., M. Caraglia, A. Budillon, M. Marra, G. Vitale, C. Viscomi, S. Masciari, P. Tassone, A. Abbruzzese, S. Venuta. 2005. New pharmacokinetic and pharmacodynamic tools for interferon-α (IFN-α) treatment of human cancer. Cancer Immunol. Immunother. 54: 1-10.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section